Abstract
Recent developments in operative and pharmacological techniques for locoregional treatment of liver malignancies have focused the interest of oncologists on this organ. With respect to indication for treatment and determination of treatment effects of systemic chemotherapy in liver tumors, a number of questions may be formulated:
-
1.
Is there anything specific in malignant liver disease as compared with involvement of other organs?
-
2.
Does liver involvement modify the indication or results of systemic treatment used in disseminated cancer?
-
3.
Is the determination of treatment effects in disseminated cancer influenced by liver involvement?
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Buroker T, Moertel C, Fleming T, Everson L, Cullinan S, Krook U, Foley J, Schutt A (1984) A randomized comparison of 5-FU containing drug combinations with 5-FU alone in advanced colorectal carcinoma. Abstract C-537. Proc Am Soc Clin Oncol 3: 138
Chabner BA, Myers CE (1982) Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology. Lippincott, Philadelphia
Cullinan S, Moertel C, Fleming T, Everson L, Krook J, Schutt A (1984) A randomized comparison of 5-FU alone (F), 5-FU + adriamycin (FA) and 5-FU + adriamycin + mitomycin C (FAM) in gastric and pancreatic cancer. Abstract C-536. Proc Am Soc Clin Oncol 3: 137
Dombernowsky P, Hirsch F, Hansen HH, Hainau B (1978) Peritoneoscopy in the staging of 190 patients with small-cell anaplastic carcinoma of the lung with special reference to subtyping. Cancer 41: 2008–2012
George SL, Hoogstraten B (1978) Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J Natl Cancer Inst 60: 731–736
Havelaar IJ, Sugarbaker PH, Vermess M, Miller DL (1984) Rate of growth of intraabdominal metastases from colorectal cancer. Cancer 54: 163–171
Ihde DC, Makuch RW, Carney DN, Bunn PA, Cohen MH, Matthews MJ, Minna JD (1981) Prognostic implication of sites of metastases in patients with small cell carcinoma of the lung given intensive combination chemotherapy. Am Rev Respir Dis 123: 500–507
Kemeny N (1983) The systemic chemotherapy of hepatic metastases. Semin Oncol 10: 148–158
Metzger U, Mermillod B, Aeberhard P, Egeli R, Laffer U, Martinoli S, Mueller W, Schroeder R, Cavalli F, Weber W (1984) Adjuvant portal liver infusion with 5-fluorouracil and mitomycin C following curative large bowel cancer surgery. In: Jones SE, Salmon SE (eds)Adjuvant therapy of cancer I V. Grune and Stratton, New York
Peto R (1978) Clinical trial methodology. Biomedicine 28: 24–36
Pikren JW, Tsukuda Y, Lane WW (1984) Liver metastases: analysis of autopsy data In: Weiss L, Gilbert HA (eds) Liver metastases. Hall, Boston
Pontes JE, Wajsman Z, Beckley S, Williams P, Murphy GP (1983) The treatment of stage III nonseminomatous testicular tumors. Cancer 51: 1327–1331
Porzsolt F, Schreml W, Mende S, Buchelt L, Knöchelmann R, Brass B, Gerteis D, Stier R (1984) A phase IV protocol for treatment of metastatic breast cancer. Abstract 5/8 GL. J Cancer Res Clin Oncol [Suppl] 107: 12
Reynolds TF, Vugrin D, Cvitkovic E, Cheng E, Braun DW, O’Hehir MA, Dukeman ME, White-more WF, Golbey RB (1981) VAB-3 combination chemotherapy of metastatic testicular cancer. Cancer 48: 888–898
Samson MK, Fisher R, Stephens RL, Rivkin S, Opipari M, Maloney T, Groppe CW (1980) Vinblastine, bleomycin and cis-diaminodichloroplatinum in disseminated testicular cancer: response to treatment and prognostic correlations. Eur J Cancer 16: 1359–1366
Sauer H (1983) Beeinflussung der Wirkung von Zytostatika. In: Drings P, Schreml W (eds) Supportive Maßnahmen bei der Internistischen Tumorbehandlung. Zuckschwerdt, München, p I75–197
Schreiber C (1984) Metastasen bei unbekanntem Primärtumor. Dissertation, Ulm
Schreml W (1985) Adjuvante Therapie gastrointestinaler Tumoren - gegenwärtiger Stand. Der informierte Arzt (in press)
Schreml W, Porzsolt F, Brass B (1985) Telefonische Beratungsstelle des Tumorzentrums Ulm - Bericht über 6 Jahre Tätigkeit. Munch Med Wschr (in press)
Seeber S, Schütte J, Niederle N, Schmidt CG (1983) Neue Ergebnisse der Behandlung metastasierender Hodentumoren im Früh-und Spätstadium. Tumor Diagn Ther 4: 45–54
Taylor J, Mullee MA, Machin D (1984) Adjuvant therapy of colorectal cancer with portal vein cytotoxic perfusion. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer I V. Grune and Stratton, New York
Ultmann JE, Phillips TL (1982) Management of the patient with cancer of unknown primary site. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of Oncology. Lippincott, Philadelphia
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Schreml, W. (1986). Indications for Treatment and Determination of Treatment Effects with Primary and Secondary Liver Tumors. In: Herfarth, C., Schlag, P., Hohenberger, P. (eds) Therapeutic Strategies in Primary and Metastatic Liver Cancer. Recent Results in Cancer Research, vol 100. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82635-1_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-82635-1_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82637-5
Online ISBN: 978-3-642-82635-1
eBook Packages: Springer Book Archive